Related Experiment Video
Updated: May 7, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Gastric cancer patients with Helicobacter pylori infection have a poor prognosis
Guanghua Li1, Zhao Wang, Zhixiong Wang
1Department of Gastrointestinal Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, PR China.
Background And Objectives:
Gastric cancer patients with Helicobacter pylori infection had been reported to have a better prognosis. However, this finding is still controversial. Our research aims to investigate the influence of H. pylori infection on the prognosis of gastric cancer patients who underwent surgery.
Methods:
The H. pylori infection status of 162 consecutive gastric cancer patients who underwent surgery was assessed in their tumor samples by immunohistochemical staining. Univariate and multivariable analysis were employed to investigate the potential impact of H. pylori infection status on the gastric cancer-specific survival and relapse-free survival of the patients.
Results:
The median follow-up period was 35.3 months (range, 1.7-71.9). Gastric cancer-specific survival was 30.2 months (95% CI 24.8-35.6) and relapse-free survival was 28.7 months (23.5-34) in H. pylori positive patients, compared with 39.8 months (34.8-44.7) and 38.1 months (33-43.2), respectively in H. pylori negative patients (P = 0.01 and P = 0.011, respectively. Multivariable analysis showed positive H. pylori infection is an independent prognostic factor for gastric cancer-specific survival (hazard ratio 1.71 [95% CI 1.11-2.66]) and relapse-free survival (hazard ratio 1.68 [95% CI 1.05-2.69]).
Conclusion:
Gastric cancer patients with H. pylori infection have poor gastric cancer-specific survival and relapse-free survival. Our finding suggested that the H. pylori infection could be an indicator for prognosis of gastric cancer patients.
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Gastritis II: Pathophysiology
Peptic Ulcer
Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
